Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 8,324	$ 2,336
Available-for-sale investments	90,342	105,575
Other receivables	426	435
Prepaid expenses	4,025	5,223
Total current assets	103,117	113,569
Property and equipment, net	433	543
Right-of-use assets	1,050	1,267
Other assets	176	158
Total assets	104,776	115,537
Current liabilities:
Accounts payable	1,563	1,031
Accrued expenses	3,694	4,002
Current portion of operating lease liability	1,012	980
Total current liabilities	6,269	6,013
Long-term operating lease liability, net of current portion	133	398
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares; Class X Convertible Preferred Stock issued and outstanding shares – 0 as of March 31, 2022 (unaudited) and December 31, 2021, respectively
Common stock, $0.001 par value per share; 42,500,000 authorized shares as of March 31, 2022 and December 31, 2021, respectively; issued and outstanding shares – 28,056,249 (unaudited) and 27,793,035 as of March 31, 2022 and December 31, 2021, respectively	28	28
Additional paid-in capital	483,730	481,832
Accumulated other comprehensive loss	(759)	(263)
Accumulated deficit	(384,449)	(372,296)
Total aTyr Pharma, Inc. stockholders’ equity	98,550	109,301
Noncontrolling interest in Pangu BioPharma Limited	(176)	(175)
Total stockholders’ equity	98,374	109,126
Total liabilities and stockholders’ equity	$ 104,776	$ 115,537